Comparison tool
Compare peptides
Pick up to three compounds. Useful for deciding whether two peptides in a stack actually do different things, or whether you're paying twice for the same pathway.
Select up to three (1/3)
| Attribute | |
|---|---|
| Category | Metabolic |
| Evidence grade | Strong |
| Also known as | Ozempic, Wegovy |
| Mechanism | Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. |
| Key benefits | ~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise |
| Side effects | Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history |
| Half-life | About 7 days |
| Administration | Once-weekly subcutaneous injection (oral tablet also approved) |
| Dosing overview | Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks |
| Storage | Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label |
| Legal status | FDA-approved and prescription-only. |
Dosing figures reflect published literature and commonly reported community protocols. They are informational only.